ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
32 announcements with these filters
Chandan Healthcare scaled its diagnostic franchise network to 500+ centres, reaching a total of 568+ centres. It targets 1,000 centres by FY27-end and 3,000 in two years.
Chandan Healthcare clarified to NSE it has one reportable segment, explaining the omission of segment-wise details in its Q4 FY27 financial results.
Chandan Healthcare Limited has allotted 5,99,998 equity shares upon conversion of fully convertible warrants, aggregating to ₹14.04 Crore.
Chandan Healthcare Ltd's board approved the appointment of an Independent Director, ratified cost auditor remuneration, and recommended varying the objects for utilising unutilised warrant proceeds.
Chandan Healthcare Limited announced the EGM voting results held on 29 August 2026. Shareholders approved the disinvestment of its entire shareholding in Chandan Pharmacy Limited.
Chandan Healthcare Limited held an EGM to approve the disinvestment of its entire stake in subsidiary Chandan Pharmacy Limited for approximately ₹16.77 Crore. This strategic divestment focuses resources on core diagnostics.
Chandan Healthcare is pivoting from pharmacy trading to a high-margin diagnostic-led strategy. The company reported healthy revenue growth but is over-relying on capital-light franchise scaling to drive future profitability.
Chandan Healthcare reported strong Q1 FY27 results with 19.62% YoY revenue growth and 42.27% EBITDA growth, driven by expansion into 15 states and diversified B2C, B2B, and B2G segments.
Chandan Healthcare Ltd reported revenue from operations of ₹80.9 Cr (+19.1% YoY) and net profit of ₹7.5 Cr (+29.3% YoY) for Q1 FY27.
Chandan Healthcare Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of proceeds from its preferential issue.
Chandan Healthcare Limited scheduled a board meeting for August 14, 2026. The meeting will consider unaudited financial results for the quarter ended June 30, 2026.
Chandan Healthcare Limited received an Administrative Warning Letter from SEBI regarding disclosure lapses in its Red Herring Prospectus. No monetary penalty was imposed.
Chandan Healthcare approved the divestment of its entire 53.56% stake in Chandan Pharmacy to group company Chandan Hospital. The transaction is valued at ₹31.31 Crore.
Chandan Healthcare Limited announced an EGM on August 29, 2026, to approve the sale of its entire 53.56% stake in Chandan Pharmacy Limited for Rs. 16.77 Crore.
Chandan Healthcare Limited scheduled an EGM for August 29, 2026. Shareholders will vote on disinvesting the entire stake in material subsidiary Chandan Pharmacy Limited.
Chandan Healthcare Limited will divest its 53.56% stake in subsidiary Chandan Pharmacy Limited for Rs.16.77 Crore. The sale is subject to shareholder approval at the upcoming EGM.
Chandan Healthcare Limited announced that Dayal Institute of Medical Sciences has withdrawn its complaints, resolving all disputes and claims between the parties amicably.
Chandan Healthcare Limited voluntarily submitted its Integrated Corporate Governance Report for the quarter ended June 30, 2026. This follows the company's proposed transition from the NSE SME platform to the Main Board.
Chandan Healthcare reported ₹48.67 Crore in quarterly operating sales, a 35.64% YoY increase. The company expanded its network by adding 140 new diagnostic centres.
Chandan Healthcare resubmitted revised audited financial results for H1 and FY ended March 2026 per exchange clarification. The filing corrects prior submission issues and includes the auditor's report.
Chandan Healthcare Limited responded to NSE’s surveillance query, stating the share price movement is market‑driven with no undisclosed information. The company affirmed compliance with SEBI LODR regulations.
Chandan Healthcare reported strong FY26 performance with Revenue of ₹280.67 Cr and PAT of ₹27.06 Cr, driven by network expansion and strategic PPP projects.
Chandan Healthcare reported robust FY26 results with 20.43% revenue growth, transitioning to a pan-India diagnostic model while scaling franchise and PPP projects.
Chandan Healthcare reported FY26 Total Income of ₹280.67 Crore and PAT of ₹27.06 Crore. The company successfully expanded its diagnostic network across 13 states.
Chandan Healthcare delivered robust FY26 growth, pivoting from a regional player to a pan-India diagnostic platform. Management remains aggressively optimistic about franchise scaling and government PPP projects despite high capital intensity.
Chandan Healthcare Ltd reported revenue from operations of ₹75.6 Cr (+20.8% YoY) and net profit of ₹6.9 Cr (+15.0% YoY) for Q4 FY26.
Chandan Healthcare Limited reported consolidated annual revenue of ₹280.67 Crore for FY26. The Board also re-appointed internal and cost auditors for the upcoming financial year.
Chandan Healthcare Limited scheduled a board meeting for May 29, 2026, to consider audited financial results. Trading window remains closed since April 1, 2026.
Chandan Healthcare Limited received an NSE clarification request regarding complaints about its Red Herring Prospectus disclosures. The company is currently preparing its formal response.
Chandan Healthcare Limited released its Monitoring Agency Report for the ₹104.13 Crore preferential issue. This report confirms the utilization status of warrant proceeds as per regulatory requirements.